---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-023320"
form_type: "8-K"
ticker: "NVNO"
cik: "0001661053"
company_name: "enVVeno Medical Corp"
filed_at: "2021-09-22T23:59:59+00:00"
generated_at: "2026-06-29T02:05:05.642937+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hancock Jaffe to rename enVVeno Medical, focus on venous disease; VenoValve trial to start

## Summary
- Name change to enVVeno Medical Corporation, tickers NVNO/NVNW effective Oct 1, 2021.
- VenoValve SAVVE pivotal trial ready to enroll 75 patients at up to 20 U.S. centers.
- Development of second venous disease product 'enVVe' initiated; expected unveil mid-2022.
- CoreoGraft cardiac bypass program discontinued to focus on venous disease.

## SEC filing metadata
- accession: 0001493152-21-023320
- form_type: 8-K
- ticker: NVNO
- cik: 0001661053
- company_name: enVVeno Medical Corp
- filed_at: 2021-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/0001493152-21-023320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661053/000149315221023320/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-023320
- JSON: https://secwatch.observer/filing/0001493152-21-023320.json
- Plain text: https://secwatch.observer/filing/0001493152-21-023320.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.